ReviewBioengineering (Basel, Switzerland)2025
Evaluation of Long-Term Outcomes of Enamel Matrix Derivative in the Treatment of Peri-Implant Disease: A Systematic Review and Meta-Analysis.
Review in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Role of Biologically Active Materials in Peri-Implant Diseases.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Enamel matrix derivative (EMD) has been proposed as an adjunctive treatment for peri-implantitis, a prevalent complication of dental implants characterized by inflammatory responses and progressive bone loss around the implant site. This study aimed to perform a systematic review and meta-analysis to evaluate the efficacy of EMD compared with control interventions in the treatment of peri-implantitis. A comprehensive literature search was conducted by two independent reviewers using a combination of Medical Subject Headings (MeSHs) and free-text terms. The search included three major electronic databases-Medline via PubMed, the Cochrane Library, and Embase-and studies published up to November 2024. The search aimed to identify relevant clinical trials assessing the long-term outcomes of EMD in peri-implantitis treatment. Out of an initial 54 articles identified, five met the inclusion criteria and were included in the meta-analysis. The pooled mean difference for probing depth reduction with EMD compared to controls was 0.88 (95% confidence of interval (CI): -1.26 to 2.02). The decrease in bleeding on probing yielded a pooled mean difference of 16.70 (95% CI: -4.93 to 38.32). For bone level gain, the pooled mean difference was 0.59 (95% CI: -0.01 to 1.19). This meta-analysis indicated that the most significant improvement with the use of EMD was observed in bone level gain with surgical approach. Moreover, the adjunctive use of EMD in the treatment of peri-implantitis may offer clinical benefits in reducing probing depth and bleeding on probing at the three-month evaluation. These findings support the consideration of EMD as a valuable adjunct in peri-implantitis treatment protocols, warranting further investigation through well-designed, long-term randomized controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.